In 2024, Johnson & Johnson's generated approximately ** billion U.S. dollars in sales. This statistic shows the global total sales of Johnson & Johnson from 2005 to 2024. Johnson & Johnson is a multinational company, specialized in pharmaceuticals, medical devices, and consumer goods. The company is headquartered in New Brunswick, New Jersey. Johnson & Johnson’s global position Johnson & Johnson has been ranked among the top pharmaceutical companies globally recently and in multiple categories. As of 2024, it was the leading pharmaceutical company worldwide in terms of total revenue generated. Furthermore, Johnson and Johnson was also the leading pharmaceutical company globally by prescription sales revenue in 2023, as well as being the second ranked company worldwide in terms of its research and development spending. Johnson & Johnson’s research and development Johnson and Johnson’s research and development expenditure has been steadily and gradually increasing in the past five years. In 2024, the company spent over ** billion U.S. dollars on research and development, accounting for some ** percent of total sales that year.

In 2024, Johnson & Johnson’s net earnings were estimated to be about 14 billion U.S. dollars. This is a significant decrease compared to the previous year, when net earnings stood at about 35 billion U.S. dollars. Johnson & Johnson’s revenue overview Johnson & Johnson is a U.S.-based multinational company that is headquartered in New Brunswick, New Jersey, in the United States. The company’s largest business segment is their pharmaceutical segment, but the company also operates in medical devices and diagnostics. Regionally, the United States is responsible for the largest proportion of Johnson & Johnson’s sales, followed by Europe. Johnson & Johnson’s global R&D positioning Johnson & Johnson has been ranked second among global pharmaceutical companies based on their dollar amount spent on research and development in 2023. Johnson & Johnson is ranked among the top 10 pharmaceutical companies based on the number of originated drugs. Similarly, Johnson & Johnson is ranked among the top seven pharmaceutical companies based on the number of drugs in development as of 2024.

Johnson and Johnson is a leading international pharmaceutical company. In 2024, among its top pharmaceutical products was Darzalex which earned some **** billion U.S. dollars of revenue. Darzalex is a drug used in the treatment of multiple myeloma and light chain amyloidosis. International pharmaceutical companies There are several major pharmaceutical companies that are making significant economic impacts globally. In 2023, Johnson & Johnson, AbbVie, and Novartis were the top pharmaceutical companies based on their prescription drug sales globally. When viewed by market capitalization, Johnson and Johnson was the third ranked global pharmaceutical company, as of 2024. Top pharmaceuticals The global pharmaceutical industry showed significant growth of revenues over the past two decades. Globally, oncology, diabetes and immunology are considered the top therapeutic areas for future growth. In 2023, when covid vaccines are excluded, Humira by AbbVie, Keytruda by Merck & Co. and Ozempic by Novo Nordisk were the top drugs based on sales worldwide.

In 2018, Johnson & Johnson generated over 12 billion U.S. dollars in revenue through immunology products. Revenue from this product category is projected to decrease in the coming years, while earnings from the oncology category are set to increase.

Johnson & Johnson’s total revenue

Johnson & Johnson’s global revenue came to some 82 billion U.S. dollars in 2019 – although this is the total revenue from all three of the company’s segments. Over the past decade, the company’s total revenue numbers have increased by almost 22 percent. The multinational, headquartered in New Jersey, earns roughly half of that revenue in its home market: in 2018, J&J generated close to 42 billion U.S. dollars in the United States. A total of approximately 15 billion U.S. dollars were made in the African and Asian Pacific regions that year.

J&J WORKFORCE

In 2017, J&J’s workforce count had, for the first time, reached and exceeded the 130 thousand mark. In 2018 specifically, just over 135 thousand people worked for Johnson & Johnson. These employees are active in various areas in over 60 countries worldwide: from pharmaceutical R&D to manufacturing and sales.

This statistic shows the total revenue of Johnson & Johnson worldwide from 2012 to 2024. Johnson & Johnson is a multinational company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2018, Johnson & Johnson's global revenue is estimated to amount to about 78.27 billion U.S. dollars.

This statistic shows the revenue of Johnson & Johnson worldwide from 2018 to 2024, by segment. Johnson & Johnson is a multi-national company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2018, the consumer healthcare segment of Johnson & Johnson is estimated to generate 3.33 billion U.S. dollars of the company's global revenue.

This statistic shows the breakdown of Johnson & Johnson's revenue worldwide from 2013 to 2021, by sub-category. Johnson & Johnson is a multi-national company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2015, 13.7 percent of Johnson & Johnson's revenue was generated by the surgical devices sub-category.

Johnson & Johnson’s medtech (medical devices and diagnostics) segment earned about **** billion U.S. dollars through its surgery franchise in 2024. Orthopedics was the second-largest franchise, generating roughly *** billion U.S. dollars that year. J&J’s revenue In 2024, Johnson & Johnson’s global revenue amounted to some ** billion U.S. dollars, which was an increase of around ***** billion U.S. dollars compared to 2023. During 2023, the consumer health business of the company was moved in a spin-off. J&J currently has two major segments: Innovative Medicine and Medtech. In 2024, over ***billion U.S. dollars were generated through the medtech division. That was roughly ** percent of the company’s total global revenue. Over the years, the multinational company with its various segments generated more than half of its revenues in the United States, making it the company’s main market. In 2024, around **** billion U.S. dollars were generated in Europe.

This statistic shows Johnson & Johnson's research and development expenditure as a percent of sales from 2005 to 2024. Johnson & Johnson is a company specialized in pharmaceuticals, medical devices and diagnostics. The company is headquartered in New Brunswick, New Jersey. In 2024, the company's R&D expenditure represented some **** percent of its total sales.

This statistic shows the global sales of Johnson & Johnson's consumer healthcare segment from 2014 to 2022 distributed by franchise. Johnson & Johnson is a multinational company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2022, Johnson & Johnson generated 1.46 billion U.S. dollars in sales with baby care products. However, during 2023, the company spun-off its consumer health business (now under the new name Kenvue).

This statistic shows Johnson & Johnson's share of the skin care products market worldwide from 2013 to 2021. In 2015, Johnson & Johnson's share of the global skin care products market is estimated to be 4.15 percent.

This statistic shows the revenue of Johnson & Johnson's consumer healthcare segment worldwide from 2013 to 2021, by product category. Johnson & Johnson is a multi-national company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2018, Johnson & Johnson's skin care segment is estimated to generate 4.46 billion U.S. dollars in revenue.

This statistic shows the percentage of Johnson & Johnson employees that were involved in research and development (R&D) activities in 2017 and 2018. In 2017, the percentage of employees involved in R&D was around 15.9 percent. As of 2018 that has increased to about 16.4 percent of employees.

As of September 6, 2021, high-income countries accounted for around 68 percent of total Johnson and Johnson vaccines delivered worldwide. The statistic illustrates the share of Johnson & Johnson COVID-19 vaccines delivered worldwide, by country income group.

The top 50 pharmaceutical companies by prescription sales in 2024 – and their research and development (R&D) spending – included big names such as Johnson & Johnson, Novartis, and AbbVie. During that year, Johnson & Johnson's Rx sales were approximately **** billion U.S. dollars. Thus, the American pharma giant was both the largest pharmaceutical company based on pure pharma revenue worldwide and the second ranked pharmaceutical company based on R&D spending. Johnson & Johnson spent over ** billion U.S. dollars on R&D in that year. Pharmaceutical R&D spending Research and development in the pharmaceutical industry involves the identification and development of compounds used to make new drugs. The pharmaceutical industry has the largest percentage of spending attributable to R&D among all industries. Research and development spending in the pharmaceutical industry around the world is increasing over time. However, there have been variations in the growth of research and development spending with a peak during the pandemic years 2020 and 2021. New pharmaceutical products The goal of R&D is to produce new drugs and compounds. Globally, the U.S. pharmaceutical industry created the largest number of new drugs and compounds between 2019 and 2023, followed by Europe. Among U.S. pharmaceutical companies, there are various levels of success for new drugs, depending on the phase of development. The data shows that between phase I and II alone, already over half of all drugs are failing.

In the fiscal year of 2024, Johnson Controls generated global net sales of almost 22.95 billion U.S. dollars. Its products and systems segments were responsible for generating most of the company's revenue.

In 2023, the North American region accounted for over half of the pharmaceutical market revenue worldwide. Since 2010, North America’s revenue share has increased by 11 percent, while Japan’s share has decreased by over six percent. Global pharmaceutical revenue The global pharmaceutical market made a grand total of around 1.6 trillion U.S. dollars in 2023. Worldwide pharmaceutical revenue had seen a steady increase every single year since 2001, when the market’s value was about two-thirds smaller. The largest submarket within this industry has been the United States recently. Pharma and biotech top companies The pharma industry is a large part of the healthcare branch and deals with the development and production of medical drugs. The leading pharmaceutical and biotechnological company according to the latest ranking, in terms of total revenue, was Johnson & Johnson, which generated over 85 billion U.S. dollars in revenue in 2023. Other large American companies in the top ten rankings included AbVie, Pfizer, and Merck & Co.

This statistic gives a breakdown of Johnson Controls International's revenue in the fiscal year of 2018, by segment. In that year, the company generated some 25 percent of its revenue from the power solutions segment. In 2018, Johnson Controls sold its Power Solutions business to Brookfield Business Partners L.P.

In 2023, the growth rate of the Brazil's pharmaceutical market stood at 9.2 percent, which was among the higher growth rates of leading national pharmaceutical markets. Pharma companies in Brazil ACHE, which is a Brazilian-owned corporation founded in 1966, is among the leading pharmaceutical companies in Brazil, with a revenue of around five billion Brazilian reals (just over one billion U.S. dollars). Around half of the top ten companies were domestic and included enterprises, such as Eurofarma, Neo Quimica, Libbs, and Mantecorp Farmasa. Pharmaceutical R&D Global pharmaceutical research and development expenditures in 2023 came to a total of over 300 billion U.S. dollars. By 2030, R&D spending is expected to exceed over 360 billion U.S. dollars, with pharmaceutical companies Roche and Johnson & Johnson being among the top leading companies.

Cette statistique présente les recettes mondiales de Johnson & Johnson entre 2005 et 2023, en millions de dollars des États-Unis. Johnson & Johnson est une société multinationale spécialisée dans les produits pharmaceutiques, les appareils médicaux et les biens de consommation. Cette entreprise est basée à New Brunswick, dans le New Jersey. En 2023, Johnson & Johnson a réalisé un chiffre d'affaires de plus de 85 milliards de dollars.